Introduction {#Sec1}
============

Cancer is a multifactorial disease harboring disorders on multiple levels, rendering a single drug to be therapeutically insufficient. Therefore, designing a single drug aiming multiple targets is a difficult proposition. Keeping this in view, multiple targeted combinatorial therapeutic regimens, to achieve enhanced therapeutic efficacy, have been the main stay of cancer treatment. However, employment of drug combinations, may present with increased drug toxicity and varied battery of side effects^[@CR1]^. Hence, foreseeing the drug side effects and probable drug adverse reactions (ADRs) encountered by patients is difficult by the existing medical literature. This in turn significantly effects quality of life of patients during treatment and disguise the patient well-being even after the treatment is concluded. Such side effects may be because of drug promiscuity or off targets interactions inducing drug-drug or drug-target interactions^[@CR2]^. As the wealth of information regarding disease state, particularly cancers and its therapies is growing, it is more evident that both on-target and off-target drug-protein interactions need to be taken in account as to predict drug specific side effect profiles. Interestingly, such off targets have been notifying their presence notably in the shape of cardiotoxicity attributable to hERG inhibition^[@CR3]^ and hepatotoxicity attributably by CYP inhibition^[@CR4]^.

Therapies for cancer can cause both central and peripheral toxicities leading to a wide differential of cognitive changes which may span from acute onset delirium like symptoms to more progressive degenerative changes and delayed neurological consequences termed as 'Chemobrain','Chemofog', 'Cancer related Cognitive Impairment' or 'Chemotherapy induced Cognitive Impairment' (CICI)^[@CR5]--[@CR10]^. Normal human cognitive process constitutes various important neurobiological processes of day to day life like attention, learning, memory, planning and decision making^[@CR11],[@CR12]^. Therefore, any interference may translate into neurodegenerative and psychiatric morbidity. The CICI can exhibit itself in varying forms ranging from but not limited to headache, seizures, acute or chronic encephalopathies, cerebrovascular disease, movement disorders and cranial neuropathies^[@CR13]^.

Previous studies addressing 'chemobrain' can be broadly segregated in to clinical and preclinical experiments^[@CR14],[@CR15]^. The clinical studies engross clinical assessment of cognitive function during and/or after chemotherapy via use of battery of neuropsychological test. Whilst, preclinical histological or behavioral studies investigate any potential connection between chemotherapy associated neurotoxicity and hippocampal neurodegeneration in cell lines and rodent models. Interestingly, neurodegeneration has not been the only backdrop of chemobrain. There is aberrant neuronal signaling and altered long term potentiation (LTP), suggesting the chemotherapy may not be toxic enough to ensue neurodegeneration, but deleterious enough to impair default neuronal functionality^[@CR16]^.

The neurological processes of learning and memory storage are reliant on active inter synaptic connectivity strength and subsequently the involvement of larger active synapses will be leading to bigger synaptic efficiency in the form of 'Long Term Potentiation' (LTP). Mechanistically and temporally, LTP can be dichotomized into Early LTP (E-LTP), which initiates following inducing stimulus lasting from few minutes to approx. 4 hours, and Late LTP (L-LTP) spanning from few hours to days, dependent on new protein synthesis^[@CR17]^. The LTP induction and maintenance is stringently managed by ionotropic Glutamate receptors (iGluR)^[@CR18]^.Aberrant activation of iGluRs may lead to fulminant neuronal death also known as glutamate excitotoxicity^[@CR19]^. One of the key regulators of LTP are NMDA-R and AMPA-R. These are voltage gated cationic channels with Ca^+2^ and Na^+^ preferences respectively^[@CR20]^. The case of iGluR being targeted by pharmacologic modulation in order to augment the excitatory neurotransmission, is more than two decades old^[@CR21]^. The rationale for drug targeting lies in the functional importance of LTP in facilitating learning and memory. The therapeutic benefit can be translated for psychiatric disorders^[@CR22]^. Therefore, any off target interaction can interfere with NMDA-R transportation and re-sculpting neuronal synapse, thereby rejuvenating synaptic efficiency in general and E-LTP in particular. This resultantly, will affect L-LTP induction which is dependent on E-LTP. The NMDA-R are also known for their critical involvement in neural cell migration and neural tube formation during embryogenesis. So evidently, alteration in their function leads to neural tube defects^[@CR23]^. Moreover, they have been targeted for therapeutic modulation for CNS disorders like Schizophrenia^[@CR24]^, Depression^[@CR25]^, Alzheimer's disease^[@CR26]^ and Epilepsy^[@CR27]^.

The signaling intricacies triggered by LTP induction is not merely linear in its path but rather involve complex interaction and crosstalk of other pathways emaciating into converging or diverging outcome which may end up in positive or negative neuro-signaling feedback loops^[@CR17]^. Substantial evidence been put forwarded that CICI may be implicated to interfere LTP^[@CR15],[@CR16]^.The investigative ground gets further complicated by considering the cancer patient specific clinico-pathological characteristic and the subsequent combination and dosage of chemotherapy administered^[@CR10]^. As most of the chemotherapeutic agents have been implicated to affect neurons by more than one mechanism, the resultant outcome of CICI may be attributed to converging and synergistic neurotoxic insults. It is also rather interesting to note that chemotherapy which generally target rapidly dividing cells, can also target very slowly reproducing cells of CNS.

Most of the drugs impart their therapeutic action by stimulating or inhibiting a disease target protein. However, they may be rendered to interact or bind with other proteins i.e. 'off-target' due to resemblances in protein binding topological state. These off-target interactions can be a probable eventuality by considering the fact that drugs rarely binds to its only actual target^[@CR28]^. Such outcome can lead to high drug attrition rate^[@CR29]^. If an off target is known to mediate a certain side effect, then this information can be potentially utilized to adjust dose, avoid drug side effect and improve management in patients for better clinical outcomes.

The spectrum of neurological deficits by CICI is encompassing almost all classes of chemotherapeutic agents which include alkylating agents, anthracyclines, DNA interfering agents, antitumor antibiotics, mitotic inhibitors, antimetabolites and anti-hormonal agents^[@CR30]--[@CR41]^. Paradoxically, the deleterious effects of these agents on brain cortical functions in general and neurodegeneration in particular are well reported^[@CR14]--[@CR16],[@CR31],[@CR42]^, however, the effect of these drugs by virtue of their off target interaction without actually killing neurons but altering their functional dynamics on a particular pathway remains elusive.

The emergence of newer biological, chemical and immunotherapeutic cancer treating agents, with various unconventional drug delivery mechanisms has created scientific plausibility to understand the role of these therapeutic agents and their cumulative outcomes to cell signaling. The advent of kinase inhibitors as chemotherapeutic agents with better blood brain barrier (BBB) permeation^[@CR43],[@CR44]^, intrathecal administration of chemotherapy for managing metastatic disease^[@CR45]^, and increasing the porosity of BBB by methamphetamine administration^[@CR46]^, markedly increase the exposure of neuronal microenvironment to chemotherapeutic drugs. It is interesting to note that the employment of *in vivo* experimental tools like yeast two hybrid system and mass spectrometry coupled with tandem affinity purification to experimentally measure protein interactions comes with high false positive rate^[@CR47]^. Keeping in view of such limitation, the *in silico* prediction tools such as Molecular Docking may provide useful illustration of given 3D drugs structure interactions with large protein datasets. Molecular Docking involves prediction of molecular mechanics among molecules by computation of polyatomic torsional angles, charges and geometry^[@CR48]^. Docking results in generation of thousands of potential poses of association in which the pose with lowest energy score is predicted to be with best binding mode. The lowest energy scoring reflects binding compactness for a particular ligand conformation bearing a physical or empirical energy function^[@CR49]^. Although docking is labor intensive, it not simply shows two interactable proteins but also how they interact^[@CR50]^. Most of the studies on drug target interactions are deploying statistical machine learning algorithms to execute high throughput screening for large drug databases and for genome wide predictions^[@CR51]--[@CR55]^. Although such methodology is useful for the intended objective, specific study of actual interactions with the corresponding target protein and the overall implication on the related pathway may be missed which can serve as a useful information for preventing adverse drug reactions. Moreover, the same information can be used for polypharmacology which is already in clinical evaluation with reference to mTOR inhibitors for varying indications such as cancer chemotherapy and Autism spectrum disorders^[@CR56]--[@CR58]^.

In spite of off-target interactions by Tamoxifen and its metabolites have been reported^[@CR59]^, there is a general dearth of information objectively elaborating the underlying biology of side effects causing chemobrain attributed to LTP interference mediated by simultaneous exposure of chemotherapeutic agents. Therefore, this study aimed to understand the drug -- protein interaction casted by various chemotherapeutic agents to the major cellular proteins involved in LTP pathway which may impact functionality of these proteins critical for learning and memory processes of brain.

Experimental Section {#Sec2}
====================

A brief workflow used for the identification of off-target interactions between LTP proteins and chemotherapeutic drugs is shown in Fig. [1](#Fig1){ref-type="fig"}.Figure 1Overall workflow of identification of off-target interactions protocol. Three dimensional structures of NMDA, AMPA, PKA, ERK, CBP and CaMKII were downloaded from protein databank and the structures of chemotherapeutic drugs were obtained from PubChem. These structures were then energy minimized. The validation of docking protocol was done by removal of co-crystallize ligand and re-docking of ligand in molecular operating environment (MOE) followed by RMSD calculation. The docking of drugs with the proteins was then performed using induced fit docking protocol. Top scoring complexes from each protein were then subjected to interaction analysis by protein ligand interaction profiler (PLIP) and PyMOL as well as for electrostatic surface calculations by PyMOL. Binding affinity analysis was done using CSM-Lig server. The ligand interaction fingerprints were calculated using MOE.

Selection of drugs {#Sec3}
------------------

In order to study the off-target interactions, most commonly used FDA approved chemotherapeutic agents were selected from National Cancer Institute (NCI) directory^[@CR60]^. Among them are alkylating agents, anti-metabolites, alkaloids, anthracyclines, aromatase inhibitors, nucleoside analogues, anti-hormonal, and antibiotics agents (Fig. [2](#Fig2){ref-type="fig"}). The structure of 65 drugs were extracted from PubChem followed by energy minimization using MMF94x force field^[@CR61]^ implemented in Molecular Operating Environment (MOE) version 2016.08. Database of drugs was then constructed for off-target interaction analysis.Figure 2Chemical structure of chemotherapeutic drugs used for identification of off-target interactions.

Selection of proteins to study off-target interactions {#Sec4}
------------------------------------------------------

In order to study the off-target interactions of chemotherapeutic drugs on the cognition, long term potentiation pathway was selected (Fig. [3](#Fig3){ref-type="fig"}). The major regulators of LTP pathway are *N*-methyl-D-aspartate receptor (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), Ca^2+^/calmodulin-dependent protein kinase II (CaMKII), protein kinase A (PKA), CREB-binding protein, and extracellular signal--regulated kinase (ERK).Figure 3The post synaptic long term potentiation (LTP) pathway^[@CR168]--[@CR170]^\*. \*Adapted from Kegg. (Pathway hsa04270). "Human Long Term Potentiation (LTP)" Retrieved 01-07-2018, from <https://www.genome.jp/dbget-bin/www_bget?hsa04720>.

Structurally, NMDARs are comprised of dimers of N subunits (N 1 & 2), which are linked together to form tetramers in a homo/hetero dimer fashion^[@CR62],[@CR63]^. Each N subunit is harboring an amino-terminal domain (ATD), followed by a Ligand Binding Domain (LBD), Transmembrane Domain and finally the C-Terminal Domain (CTD) oriented intracellularly^[@CR64]^. The ligand binding domain of NMDA composed of two subunits NR1 and either NR2A/B/C or D. Our study involved NR2A which is further composed of S1 (462--502 a.a) and S2 (664--720 a.a) similarly NR1 is contributing to LBD involved residues of S1(480--526 a.a) and S2 (682--740 a.a) subunits.

In case of AMPA, the ligand binding domain falls into S1 (393--506 a.a) and S2 (632--733 a.a) domain. In case of AMPA the ZK1 antagonist bound to the ligand binding domain.

CaMKII composed of kinase domain (1--273 a.a), the regulatory segment (274--314 a.a), and hub domain (315--475 a.a). Regulatory segment further composed of R1 (274--291 a.a), R2 (292--297 a.a) and R3 (298--314 a.a) subunits. The CaM binding residues span residues 290 to 314 within this segment. Any ligand/ inhibitor bound to the regulatory subunit alter the function of CaMKII (A mechanism of tunable autoinhibition).

PKA functions with the help of 2 regulatory and 2 catalytic subunits, assembling into a tetrameric holoenzyme. PKA consists of CaMKII binding domain-A and B (CBD-A and CBD-B). the R1α comprises both CBDs with sequence from 91--379 a.a. Within this region there are several sub domains with major allosteric or binding hot spots include, the N3A motif (residues 119--150 a.a), the β2--3 loop (residues 163--171 a.a), the base binding region (BBR) (residues 180--193 a.a), the phosphate binding cassette (PBC) (residues 199--211 a.a), and the hinge (residues 226--251 a.a). Another important domain in the PKA is the glycine rich loop (50--55 a.a) and the ribose binding pocket^[@CR65],[@CR66]^.

Human ERK2 is spanning on 360 amino acids. Structurally they are similar to other kinases which constitutes protein kinase domain (25--313 aa)^[@CR67]^. This domain harbors α and β helices which further host glycine rich loop (32--37 a.a), hinge region (106--109) and ATP phosphate binding loop^[@CR68]^.

Computational studies on human CREB are scarcely available probably because of its unstructured and intrinsically disordered behavior in solution^[@CR69],[@CR70]^. This can render interaction prediction against CREB with computational inaccuracies. Therefore, we restricted our docking analysis with CBP which itself is harboring intrinsically disordered regions.

Human CREB binding protein (CBP) comprises of 2442 amino acids, almost 50% of which is reported to be intrinsically disordered. CBP constitutes a histone acetyl transferase (HAT) domain, bromo domain (BRD), KID binding domain (KIX), plant homeodomain (PHD) and transcriptional activator zinc finger (TAZ) domain^[@CR71]--[@CR73]^.

Protein structure preparation {#Sec5}
-----------------------------

The atomic coordinates of proteins, NMDA (pdb ID = 5KDT), AMPA (pdb ID = 5KBV), CaMKII (pdb ID = 3SOA), PKA (pdb ID = 4UJA), CBP (pdb ID = 4NR5), and ERK (pdb ID = 2OJJ), were retrieved from Protein Data Bank. The details of all the structures are shown in Table [1](#Tab1){ref-type="table"}. Proteins retrieved from the Pdb contained water molecules and also the original ligand/substrate/inhibitor. Thus, for the preparation of the proteins structures for ligand docking, co-crystallized ligand and any water molecules present were removed followed by protonation and energy minimization using AMBER 99 force field in MOE.Table 1List of proteins used in the study for docking analysis.ProteinPDB IDResolution (Å)Structure TitleLigandSpecieRefNMDA5KDT2.44Structure of the human GluN1/GluN2A LBD in complex with GNE0723(1\~{R},2\~{R})-2-\[7-\[\[5-chloranyl-3-(trifluoromethyl)pyrazol-1-yl\]methyl\]-5-oxidanylidene-2-(trifluoromethyl)-\[1,3\]thiazolo\[3,2-a\]pyrimidin-3-yl\]cyclopropane-1-carbonitrileHomo sapiens^[@CR171]^AMPA5KBV6.8Cryo-EM structure of GluA2 bound to antagonist ZK200775 at 6.8 Angstrom resolution{\[7-morpholin-4-yl-2,3-dioxo-6-(trifluoromethyl)-3,4-dihydroquinoxalin-1(2H)-yl\]methyl}phosphonic acidRattus norvegicus^[@CR75]^ERK2OJJ2.4Crystal structure of ERK2 in complex with (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide(s)-n-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamideHomo sapiens^[@CR78]^PKA4UJA1.93Protein Kinase A in complex with an Inhibitor7-{(3S,4R)-4-\[(5-bromothiophen-2-yl)carbonyl\]pyrrolidin-3-yl}quinazolin-4(3 H)-oneHomo sapiens^[@CR77]^CBP4NR51.66Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole ligand5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-\[2-(morpholin-4-yl)ethyl\]-2-(2-phenylethyl)-1H-benzimidazoleHomo sapiensTo be publishedCaMKII3SOA3.5Full-length human CaMKII4-\[(2,4-dichloro-5-methoxyphenyl)amino\]-6-methoxy-7-\[3-(4-methylpiperazin-1-yl)propoxy\]quinoline-3-carbonitrileHomo sapiens^[@CR76]^

Docking protocol {#Sec6}
----------------

The docking studies were performed using induced fit docking (IFD) protocol implemented in MOE version 2016.08^[@CR74]^. For each docking run, the active site was identified on the basis of interaction of co-crystallized ligand with each protein. The co-crystallize ligand 6RV had been bound to the ligand binding domain of NMDA. For docking the 5 Å area around the interacting residues of NMDA (S1 and S2 domain) with 6RV was selected as active site (Volgraf *et al*. 2016). In AMPA, the co-crystallize ligand had been ZK1 bound at the ligand binding domain. A 5 Å area around the important residues that involved in interaction with ZK1 was selected as active site for docking of library of compounds^[@CR75]^. In case of CaMKII, the bound inhibitor had been Bosutinib, targeting its regulatory domain, hence the 5 Å area around the Bosutinib binding pocket was selected as active site for further docking studies^[@CR76]^. In case of PKA, the inhibitor 4L7 had been bound to glycine rich loop and β2--3 loop (ribose pocket). The 5 Å area around the residues involved in interactions with 4L7 was used as active site for docking studies^[@CR77]^. In ERK2, the co-crystallize ligand had been 82 A that bound to protein kinase and glycine rich loop. A 5 Å area around the protein kinase and glycine rich loop was selected as active site for docking of compound's library^[@CR78]^. In case of CBP, the bound ligand had been 2LL attached to its bromo domain. The 5 Å area around the important residues that involved in interactions was selected for docking studies. The docking calculation were performed using triangle match as placement method with London DG as scoring function and re-scoring was performed with GBVI/WSA dG^[@CR79],[@CR80]^. This was followed by ranking of the lowest energy protein-ligand interaction poses. The complexes with most negative IFD scores were considered carrying favorable binding. The validation step of docking protocol was performed through re-docking of the same default ligand with RMSD calculations. After re-docking, the RMSD value of co-crystallized and re-docked ligand was calculated. After the validation of docking protocol through re-docking, the library of chemotherapeutic compounds were docked into the binding domains of NMDA, AMPA, PKA, CBP, CaMKII, and ERK using the same protocol. The protocol generated 30 conformational poses for each drug with all selected proteins. The poses were re-scored by using GBVI/WSA Dg scoring function.

Binding affinity analysis {#Sec7}
-------------------------

The scoring analysis of each protein with the studied drugs was performed using box-plot function in R-3.3.3 package. On the basis of docking scores, top five complexes for each protein with studied drugs were selected for interaction analysis. The interaction analysis was performed using protein ligand interaction profiler (PLIP) server^[@CR81]^ and PyMOL (PyMOL, Molecular Graphics System, Version 2.0 Schrodinger, LLC). To further verify the interactions between docked complexes, protein ligand interaction fingerprints (PLIF) were calculated using PLIF algorithm implemented in MOE^[@CR79],[@CR80]^. PLIF summarizes the interactions like H-bonds, ionic and surface contacts on the basis of fingerprint scheme that is representative of ligand-protein complex^[@CR79],[@CR80]^. In order to further probe off-target interactions by top scoring chemotherapeutic drugs, the binding affinity of the top scoring docked complexes were calculated using CSM-Lig^[@CR82]^. CSM-Lig predict the binding affinity of a protein-small molecule complex based on structural signatures and machine learning algorithm^[@CR82]^.

Physicochemical attributes of binding region {#Sec8}
--------------------------------------------

The three dimensional illustration of charge distribution among molecules is depicted by Electrostatic potential maps, also known as electrostatic potential energy maps. These maps aid in determination of variably charged regions of a molecule which can help in identifying intermolecular interactions and molecular properties of small molecules^[@CR83]^. To understand the binding surfaces of NMDA, AMPA, PKA, CBP, CaMKII, and ERK, electrostatic charge distribution were studied using APBS plugins in PyMol.

Results {#Sec9}
=======

Interaction analysis with LTP proteins {#Sec10}
--------------------------------------

The off-targets of drugs were identified on the basis of docking scores (lower the scores, strong is the interactions).

The docking scores of all the studied protein are presented in the form of box plot (Fig. [4](#Fig4){ref-type="fig"}). According to box plot, the ERK protein (a protein kinase) is having the median score of −7.8 with 75% of data in the upper quartile and 25% of data in the lower quartile. The median score of NMDA (a receptor protein) is −7.4 with 75% of data in upper quartile and 25% of data in lower quartile. PKA is a protein kinase with median score of −7.1 with 70% and 30% of data in upper and lower quartile, respectively. Another receptor protein of LTP pathway is AMPA having the median score of −7.0. In AMPA, 70% of data is present in upper quartile and 30% of data is in lower quartile. CaMKII, a kinase protein is having different distribution of data with 25% of data is in upper quartile and 75% of data is in lower quartile with median score of −6.8. CBP is a nuclear protein with the highest median value of −6.2 and with equal distribution of data in both quartiles.Figure 4Box plot of docking scores generated by MOE. Y-axis represent the scores while X-axis represent the name of proteins. NMDA *(N*-methyl-D-aspartate receptor), AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor), CaMKII (Ca^2+^/calmodulin-dependent protein kinase II), PKA (protein kinase A), ERK (extracellular signal--regulated kinase), and CBP (CREB-binding protein).

The scores of all the chemotherapeutic drugs on the basis of their interactions with all the studied proteins is shown in Fig. [5](#Fig5){ref-type="fig"}. According to median values, Dactinomycin is having the lowest median scores of −10.8 with 100% of data present in upper quartile. Temsirolimus is having a median score of −10.3 with almost equal data distribution in both the quartile. Everolimus is having the median score of −9.7 with 15% of data in lower quartile and 85% of data in upper quartile. Bromocriptine and Docetaxel are having the same median score of −9.0 but with different distribution of data. In Bromocriptine, 60% of data in the lower quartile and 40% of data in upper quartile while in Docetaxel 75% of data in lower quartile and 25% of data in the upper quartile. Teniposide and Irinotecan having the median scores of −8.9 and −8.8, respectively. In, Teniposide 5% of data in upper quartile and 95% of data in lower quartile while in Irinotecan 85% of data in lower quartile and 15% of data in upper quartile. Paclitaxel, and Etoposide are having the median score of −8.6 but with different distribution of data. In paclitaxel 10% of data is in upper quartile and 90% of data is in lower quartile, while etoposide 100% of data present at the median. The median score of Afatinib is −8.4 with equal distribution of data in both quartiles. The drugs with the median scores in the range of −5 to −6 are Asparaginase, Busulfan, Carmustine, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Decitabine, Exemestane, Fludarabine, Gemcitabine, Ifosfamide, Letrozole, Lomustine, Melphalan, Mitomycin, Prednisone, Streptozocin, Temzolomide, Thalidomide, Thioguanine, and Thiotepa. The drugs with median scores above −4.5 are Fluorouracil, Hydroxyurea, Mercaptopurine.Figure 5Box plot of docking scores generated by MOE. Y-axis represent the scores while X-axis represent chemotherapeutic drugs. Dactinomycin, temsirolimus and Everolimus are the drugs that are having minimum docking scores.

### Interaction of Drugs with NMDA {#Sec11}

The re-docking of co-crystallize ligand was performed into the binding pocket of NMDA with overall score of −7.3 Kcal/mol and RMSD value 3.8 Å. Figure [6](#Fig6){ref-type="fig"} is showing the original and re-docked conformation of 6RV into the binding pocket of NMDA. After the successful re-docking, the docking of library of compounds were performed using the same protocol. For each compound, 30 conformations were explored and the top scoring docking poses of each compound were further used for studies. The details of docking scores of each compound is shown in Supplementary Fig. [S1](#MOESM1){ref-type="media"}. Top five docking complexes were further evaluated for ligand protein interactions (Fig. [7](#Fig7){ref-type="fig"}). The docking scores of Dactinomycin, Temsirolimus, Everolimus, Docetaxel, and Teniposide are considerably lower in comparison to that of the bound inhibitor (6RV), thus displaying the superior binding affinity of chemotherapeutic drugs to NMDA. Dactinomycin binds with a score of −11, Temsirolimus with −10.4, Everolimus with −10.2, docetaxel with −8.9, and Teniposide with −8.8. The docking scores were further validated by calculating ligand binding affinities of top five complexes. Ligand binding affinities are corresponding to the docking scores. The drug with the highest docking score is predicted to be with greater affinity for NMDA. Dactinomycin is having the highest binding affinity for NMDA with energy value of 37.0. Temsirolimus and Everolimus are having the binding affinity values of 31.3 and 31.1, respectively. All five drugs have shown interactions with Tyr 237 A, Leu 245B, and ILE 238 A, involved in hydrophobic interactions while Arg 287B involved in H-bonding (Table [2](#Tab2){ref-type="table"}).Figure 6The re-docked pose of 6RV. The co-crystallized ligand is shown in cyan while the re-docked ligand is shown in purple.Figure 7Top scoring docking conformation of NMDA with (**A**) Dactinomycin (green); (**B**) Temsirolimus (yellow); (**C**) Everolimus (beige); (**D**) Docetaxel (golden); and (**E**) Teniposide (purple). Glu N1 residues shown in white while Glu N2A residues shown in blue.Table 2Interacting residues of NMDA with Dactinomycin, Temsirolimus, Everolimus, Docetaxel, and Teniposide.DrugsBinding Affinity (−log~10~(K~D~\|K~i~))Protein ResidueDistance (Å)Type of InteractionsDactinomycin37.0GLU 230B3.61HydrophobicTYR 237A3.74HydrophobicLEU 245B3.61HydrophobicGLU 230B2.20H-bondARG 287B3.60H-bondTemsirolimus31.1TYR 237A3.94HydrophobicILE 238A3.80HydrophobicGLU 244B3.73HydrophobicLEU 245B3.50HydrophobicLEU 279A3.82HydrophobicASN 219A3.44H-bondASP 282B2.53H-bondARG 287B3.50H-bondEverolimus31.3ASN 219A3.79HydrophobicSER 235A3.66HydrophobicTYR 237A3.32HydrophobicILE 238A3.94HydrophobicLEU 245B3.09HydrophobicGLU 230B1.63H-bondLEU 245B3.27H-bondGLU 275A3.11H-bondDocetaxel29.4ALA 216A3.59HydrophobicASN 219A3.86HydrophobicILE 238A2.65H-bondARG 287B2.34H-bondTeniposide−45.2ILE 238A3.97HydrophobicLEU 245B3.76HydrophobicMET 278B3.70HydrophobicASN 219A3.25H-bondTYR 237A3.25H-bondILE 238A2.30H-bondLEU 245B2.89H-bond

### Interaction of Drugs with AMPA {#Sec12}

The validity of docking protocol was done through re-docking of ZK1 (co-crystallize ligand) into the active site of AMPA. ZK1 was re-docked with energy value of −6.99 Kcal/mol and RMSD of 1.5 Å (Fig. [8](#Fig8){ref-type="fig"}). Using the same docking protocol, the docking of our library of compounds into the ligand binding domain (S1 (393--503 a.a) and S2 (632--773 a.a)) of AMPA, were performed. For each compound 30 different docking conformations were generated (Fig. [S2](#MOESM1){ref-type="media"}) and the top scoring docking conformations were further explored for ligand binding interactions. The ligands bind to the ligand binding domain with a much higher affinity compared to that of the allosteric site. This is shown by the differences in docking scores. In the ligand binding domain, the co-crystallize inhibitor binds with a binding strength of −6.99 Kcal/mol. While Dactinomycin, Temsirolimus, Paclitaxel, Vincristine, and Irinotecan binds with scores of −11.8, −11.2, −9.9, −9.5, and −9.1 Kcal/mol, respectively. The ligand binding affinities are comparable to the docking scores with Temsirolimus is having highest affinity for AMPA and Irinotecan is the least. Individual ligand binding interactions are shown in Fig. [9](#Fig9){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}. All five drugs showing the hydrophobic interactions with Tyr450 and Leu 498 while H-bonding with Ser 654 and Glu 705.Figure 8The re-docked conformation of ZK1. The co-crystallized ligand is shown in cyan while the re-docked ligand is shown in purple.Figure 9Top ranking docking poses of AMPA with (**A**) Dactinomycin (green); (**B**) Temsirolimus (yellow); (**C**) Paclitaxel (silver); (**D**) Vincristine (golden); and (**E**) Irinotecan (maroon).Table 3Interacting residues of AMPA with Dactinomycin, Temsirolimus, Paclitaxel, Vincristine, and Irinotecan.DrugsBinding Affinity (−log~10~(K~D~\|K~i~))Protein ResidueDistance (Å)Type of InteractionsDactinomycin37.1LEU 4103.91HydrophobicTYR 4503.29HydrophobicLEU 4982.54HydrophobicLEU 6503.87HydrophobicSER 6542.75H-bondTHR 6552.13H-bondGLU 7052.80H-bondTemsirolimus38.2GLU 4023.90HydrophobicTYR 4503.65HydrophobicPRO 478478HydrophobicTHR 4823.93HydrophobicPRO 4942.99HydrophobicLEU 4982.78HydrophobicGLU 7053.77HydrophobicMET 7082.32HydrophobicLYS 7303.30HydrophobicTYR 7323.85HydrophobicSER 6542.82H-bondGLU 7052.98H-bondGLY 7312.89H-bondPaclitaxel36.1TYR 4053.03HydrophobicTYR 4503.80HydrophobicTHR 4803.56HydrophobicLEU 4983.66HydrophobicPHE 6583.71HydrophobicGLU 7053.29HydrophobicLYS 7303.00HydrophobicSER 6542.42H-bondTHR 6862.77H-bondVincristine34.4GLU 4023.56HydrophobicTYR 4503.11HydrophobicLEU 6503.38HydrophobicPHE 6583.99HydrophobicLYS 7303.01HydrophobicSER 6541.74H-bondTHR 6553.15H-bondTHR 6861.87H-bondGLU 7052.66H-bondTYR 7322.95H-bondIrinotecan35.1GLU 4022.71HydrophobicTYR 4503.03HydrophobicTHR 4803.47HydrophobicLEU 4983.35HydrophobicGLU 7053.02HydrophobicMET 7082.22HydrophobicLYS 7303.55HydrophobicTHR 6861.80H-bondTYR 4503.52Pi-stacking

### Interaction of Drugs with PKA {#Sec13}

The crystal structure of PKA was retrieved with 4L7 as co-crystallized ligand. 4L7 was re-docked into the binding pocket of PKA with binding affinity of −6.1 Kcal/mol (Fig. [10](#Fig10){ref-type="fig"}).Figure 10The original and re-docked conformation of 4L7. The co-crystallized ligand is shown in cyan while the re-docked ligand is shown in purple.

The library of chemotherapeutic drugs were docked into the binding pocket of PKA and 30 conformations per compound were generated. The detail of docking scores of all the compounds is shown in Fig. [S3](#MOESM1){ref-type="media"}. Among all the docked conformations, top five docking complexes were further studied for ligand binding interactions (Fig. [11](#Fig11){ref-type="fig"}; Table [4](#Tab4){ref-type="table"}). On the basis of docking scores, it has been observed that the studied drugs are having better affinity for PKA compared to co-crystallized ligand. Dactinomycin, Temsirolimus, Everolimus, Docetaxel and Bromocriptine bind with the PKA with scores of −10.7, −10.6, −9.7, −9.5, and −9.3 Kcal/mol, respectively. Ligand binding affinities of top five complexes are shown in Table [4](#Tab4){ref-type="table"}. Dactinomycin is having the highest binding affinity for PKA with score of 39.1 while bromocriptine is having the least binding affinity for PKA. All the five drugs having hydrophobic interactions with Phe 54, Val 57, and H-bonding with Thr 51 in the glycine rich loop of PKA. In β2--3 loop, Lys 168 involved in either H-bonding or formed salt bridge with ligand atoms. In phosphate binding cassette, Pro 202 also involved in hydrophobic interactions.Figure 11Top five docking conformations of PKA with (**A**) Dactinomycin (green); (**B**) Temsirolimus (yellow); (**C**) Everolimus (beige); (**D**) Docetaxel (golden); and (**E**) Bromocriptine (cyan).Table 4Interacting residues of PKA with Dactinomycin, Temsirolimus, Everolimus, Docetaxel, and Bromocriptine.DrugsBinding Affinity (−log~10~(K~D~\|K~i~))Protein ResidueDistance (Å)Type of InteractionsDactinomycin39.1PHE 543.03HydrophobicVAL 573.92HydrophobicLYS 723.55HydrophobicLEU 823.95HydrophobicGLU 1703.57HydrophobicPHE 1873.74HydrophobicPRO 2023.93HydrophobicTHR 512.12H-bondSER 532.34H-bondLYS 1685.13Salt bridgeTemsirolimus35.5PHE 543.35HydrophobicVAL 573.32HydrophobicPHE 1293.26HydrophobicPRO 2023.72HydrophobicTHR 512.47H-bondLYS 722.33H-bondLYS 1682.56H-bondLYS 1685.48Salt bridgeEverolimus37.3PHE 543.21HydrophobicPHE 1293.43HydrophobicGLU 1703.72HydrophobicTHR 513.96HydrophobicSER 533.28H-bondARG 1331.94H-bondLYS 1683.18H-bondDocetaxel38.2PHE 543.25HydrophobicVAL 573.52HydrophobicLEU 743.52HydrophobicPHE 1293.21HydrophobicPHE 1873.34HydrophobicPRO 2023.73HydrophobicTYR 3303.84HydrophobicLYS 1682.39H-bondGLU 1703.17H-bondLYS 724.87Pi-stackingLYS 1684.86Salt bridgeBromocriptine33.8PHE 543.78HydrophobicLYS 723.45HydrophobicLEU 743.52HydrophobicGLU 1703.84HydrophobicTHR 512.66H-bondLYS 721.59H-bondLYS 1683.70Salt bridgeGLU 1705.34Salt bridge

### Interaction of Drugs with CaMKII {#Sec14}

The co-crystallize ligand into the binding pocket of CaMKII is Bosutinib present in the regulatory domain of CaMKII. The Bosutinib was re-docked into the binding domain of CaMKII with binding score of −8.0 Kcal/mol (Fig. [12](#Fig12){ref-type="fig"}).Figure 12The co-crystallize and re-docked conformation of Bosutinib. The co-crystallized ligand is shown in cyan while the re-docked ligand is shown in purple.

Library of compounds were docked into the active site of CaMKII with binding energies ranging from −10 to −4 Kcal/mol (Fig. [S4](#MOESM1){ref-type="media"}). On the basis of binding affinities, our analysis suggested Irinotecan, Bromocriptine, Dasatinib, Afatinib, and Imatinib were having better affinity for CaMKII with scores of −10.2, −10.2, −9.6, −9.3, and −9.2 Kacl/mol, respectively, compared to Bosutinib. Irinotecan and Bromocriptine are having the same docking scores but bromocriptine having the highest binding affinity for CaMKII compared to Irinotecan. Dasatinib, Imatinib and Afatinib are also having the binding affinities comparable to docking scores (Table [5](#Tab5){ref-type="table"}). All the five compounds showing interactions in the CaM binding domain where Lys 300, and Leu 308 involved in hydrophobic interactions while Arg 297 involved in H-bonding. Leu 221 in the kinase domain also showing hydrophobic and H-bond interactions with the compounds (Fig. [13](#Fig13){ref-type="fig"}; Table [5](#Tab5){ref-type="table"}).Table 5Interacting residues of CaMKII with Irinotecan, Bromocriptine, Dasatinib, Afatinib, and Imatinib.DrugsBinding Affinity (−log~10~(K~D~\|K~i~))Protein ResidueDistance (Å)Type of InteractionsIrinotecan39.6THR 1763.21HydrophobicPRO 1773.63HydrophobicLEU 2212.33HydrophobicARG 2963.91HydrophobicLYS 3003.70HydrophobicALA 3022.66HydrophobicLEU 3082.93HydrophobicTHR 1762.73H-bondTRP 2142.10H-bondARG 2961.78H-bondARG 2972.04H-bondLYS 3002.74H-bondLYS 1374.48Salt BridgeBromocriptine42.8THR 1763.65HydrophobicGLU 2163.19HydrophobicGLN 2182.81HydrophobicLEU 2212.79HydrophobicARG 2973.80HydrophobicLYS 3003.76HydrophobicVAL 3063.41HydrophobicLEU 3082.37HydrophobicTYR 1792.14H-bondLEU 3081.04H-bondLYS 3005.35Salt bridgeDasatinib39.5LEU 2212.91HydrophobicLYS 3003.78HydrophobicTHR 3103.88HydrophobicILE 3212.27HydrophobicGLU 1393.53H-bondGLU 1394.82Salt bridgeAfatinib38.3ARG 2973.83HydrophobicVAL 3063.73HydrophobicLEU 3082.38HydrophobicLYS 3001.36H-bondLeu 3082.53H-bondGLU 3255.03Salt bridgeImatinib40.3THR 1763.82HydrophobicASP 2173.94HydrophobicGLN 2183.91HydrophobicARG 2973.74HydrophobicLYS 3003.41HydrophobicLEU 3083.23HydrophobicTHR 3103.71HydrophobicILE 3213.06HydrophobicLYS 3002.70H-bondTHR 3102.77H-bondGLU 1393.34Salt bridgeFigure 13Top five docking conformations of CaMKII with (**A**) Irinotecan (maroon); (**B**) Bromocriptine (cyan); (**C**) Dasatinib (olive green); (**D**) Afatinib (blue); and (**E**) Imatinib (brown).

### Interaction of Drugs with ERK {#Sec15}

The re-docked conformation of 82A and the original co-crystallize conformation is shown in Fig. [14](#Fig14){ref-type="fig"}. The 82A bound to ERK with energy value of −8.4 Kcal/mol and RMSD of 3.3 Å.Figure 14The co-crystallize and re-docked conformation of 82A. The co-crystallized ligand is shown in cyan while the re-docked ligand is shown in purple.

The library of compounds were docked into the binding pocket of ERK and the detail scores of all the compounds is shown in Fig. [S5](#MOESM1){ref-type="media"}. The results showed that the studied drugs are showing better affinity to ERK compared to original co-crystallize ligand. Dactinomycin, Bromocriptine, Temsirolimus, Everolimus, and docetaxel having −11.0, −10.3, −10.2, −10.1, −10.0 Kcal/mol binding affinity for ERK. On the basis of ligand binding affinities Everolimus having the highest affinity for ERK. Dactinomycin and Temsirolimus are having the same binding affinity value of 37 for ERK (Table [6](#Tab6){ref-type="table"}). The interactions of ERK with the drugs showed that Tyr 36, Val 39 involved in hydrophobic while Lys 151 involved in H-bonding with all the five drugs (Fig. [15](#Fig15){ref-type="fig"}; Table [6](#Tab6){ref-type="table"}).Table 6Interacting residues of ERK with Dactinomycin, Bromocriptine, Temsirolimus, Everolimus, and Docetaxel.DrugsBinding Affinity (−log~10~(K~D~\|K~i~))Protein ResidueDistance (Å)Type of InteractionsDactinomycin37.7ILE 313.63HydrophobicALA 353.61HydrophobicTYR 363.96HydrophobicVAL 393.53HydrophobicGLU 533.49H-bondARG 672.18H-bondLYS 1514.00Salt bridgeBromocriptine32.7VAL 393.47HydrophobicALA 523.71HydrophobicLYS 543.88HydrophobicILE 843.06HydrophobicLEU 1563.97HydrophobicTYR 362.08H-bondGLY 373.45H-bondLYS 542.17H-bondASP 1672.74H-bondASP 1113.15Halogen bondLYS 1143.92Halogen bondARG 674.55Salt bridgeTemsirolimus37.8TYR 363.51HydrophobicVAL 393.34HydrophobicTYR 1133.97HydrophobicLEU 1563.70HydrophobicGLU 333.07H-bondLYS 542.42H-bondARG 673.11H-bondGLU 712.55H-bondSER 1532.98H-bondLYS 1145.29Salt bridgeLYS 1513.93Salt bridgeEverolimus41.2VAL 393.49HydrophobicLEU 1703.72HydrophobicGLU 332.89H-bondTYR 361.83H-bondLYS 542.68H-bondTYR 643.08H-bondGLU 711.90H-bondASP 1673.31H-bondLYS 1513.21Salt bridgeDocetaxel38.3ILE 313.54HydrophobicALA 353.76HydrophobicTYR 363.83HydrophobicVAL 393.50HydrophobicALA 523.59HydrophobicILE 563.49HydrophobicTYR 643.67HydrophobicILE 843.26HydrophobicLEU 1563.49HydrophobicALA 353.09H-bondLYS 542.73H-bondLYS 1512.21H-bondASN 1543.42H-bondASP 1672.57H-bondLYS 545.04Salt bridgeARG 674.76Salt bridgeFigure 15Top five docking conformations of ERK with (**A**) Dactinomycin (green); (**B**) Bromocriptine (cyan); (**C**) Temsirolimus (yellow); (**D**) Everolimus (beige); and (**E**) Docetaxel (golden).

### Interaction of Drugs with CBP {#Sec16}

In case of CBP the original docked ligand is 2LL which was re-docked with binding score of −6.0 Kcal/mol and RMSD of 3.1 Å (Fig. [16](#Fig16){ref-type="fig"}). The docking of library of compounds were performed and the scores of each docking conformation is shown in Fig. [S6](#MOESM1){ref-type="media"}. On the basis of scores, it is obvious that CBP does not showing high affinity for the studied drugs when compared with NMDA, AMPA, ERK, PKA, and CaMKII.Figure 16The co-crystallize and re-docked conformation of 2LL. The co-crystallize ligand is shown in cyan while re-docked ligand is shown in purple.

Electrostatic potential of proteins {#Sec17}
-----------------------------------

The electrostatic potential of NMDA, AMPA, ERK, PKA, and CaMKII is shown in Fig. [17](#Fig17){ref-type="fig"}. On the basis of electrostatic potential the active site of PKA, and NMDA is more electronegative, in case of ERK it is more electronegative, in case of AMPA it is having the electropositive as well as electronegative residues while in case of CaMKII it is almost neutral. The electropositivity and electronegativity favors the strong interactions of ligand with the proteins which is also evident with the binding affinity of Dactinomycin, Temsirolimus, and Everolimus. These drugs are showing highest binding affinity for NMDA, ERK, PKA, and AMPA. While in the neutral binding pocket of CaMKII, Irrinoteacn and Bromocriptine having the high binding affinity.Figure 17Electrostatic charge distribution at binding interfaces. (**A**) Electrostatic potential map of ERK complexed with Dactinomycin, Bromoriptine, Temsirolimus, Everolimus and Docetaxel. (**B**) Electrostatic potential map of NMDA complexed with Dactinomycin, Temsirolimus, Everolimus Docetaxel and Teniposide; (**C**) Electrostatic potential map of PKA complexed with Dactinomycin, Temsirolimus, Everolimus Docetaxel and Bromocriptine; (**D**) Electrostatic potential map of AMPA complexed with Dactinomycin, Temsirolimus, Paclitaxel, Vincristine and Irinotecan; (**E**) Electrostatic potential map of CaMKII complexed with Irinotecan, Bromocriptine, Dasatinib, Afatinib and Imatinib.

Plif analysis {#Sec18}
-------------

The protein ligand interaction fingerprints were calculated using MOE. Dactinomycin, Temsirolimus and Everolimus are the drugs that are showing maximum affinity for NMDA, AMPA, PKA and ERK, hence the PLIF analysis were performed for all the three drugs in order to find any common functional group in all the compounds. On the basis of PLIF analysis it is revealed that due to large molecular structure of Dactinomycin, it has many interacting points with the active site residues of NMDA, AMPA, PKA, and ERK. It can involve in H-bonding due to the presence of carboxyl group as well as in hydrophobic interactions due to the presence of benzene ring (Fig. [S7](#MOESM1){ref-type="media"}). Temsirolimus can also involve in H-bonding due to the presence of terminal hydroxyl group and also in hydrophobic interactions with the help of long alkane chain with the active site residues of NMDA, PKA, AMPA, and ERK (Fig. [S8](#MOESM1){ref-type="media"}). Everolimus is involve in H-bonding with the help of its hydroxyl and carboxyl group while its pyrimidine ring involved in hydrophobic interactions with NMDA, PKA and ERK (Fig. [S9](#MOESM1){ref-type="media"}).

Discussion {#Sec19}
==========

The neurons of central and peripheral nervous system as well as oligodendrocytes are particularly susceptible to off target side effects pitched in by chemotherapy^[@CR30],[@CR84]^. These off target effects may contemplate into revamping functions of both dividing and non-dividing cells both at central and peripheral levels. The proposed mechanisms put forwarded to explain these pathologies include faulty DNA repair mechanisms, blood brain barrier dysfunction, disordered immune regulation and impaired neurotransmitter signaling^[@CR85]^. There is an increasing evidence that CICI disrupts neurogenesis particularly in adult hippocampus^[@CR14],[@CR16]^. The implication of such reformation results in alteration of hippocampal neural circuitry which critically affects not only memory formation and learning acquisition, but also interregional articulation of anatomically distant but functionally cognate brain regions^[@CR86]^. This can be further inferred from the reported clinical evidence of frontal cortical deficits by chemobrain^[@CR87]^. Therefore, synaptic plasticity functions mediated by neurons of hippocampus are at stake.

The focus of the study is to investigate the interactions of various chemotherapeutic drugs against major proteins involved in LTP pathway, by docking algorithm as their interacting residues may provide useful insight into functional alteration which can be related to cognitive processes. The results derived from this study revealed that Dactinomycin, Temsirolimus, Everolimus, Docetaxel and Teniposide are top 5 drugs interacting with NMDA residues located in Ligand Binding Domain (LBD) of GluN2 near Glutamate binding pocket (Fig. [7](#Fig7){ref-type="fig"}). Contextually, NMDARs have been focus of pharmacological modulation by virtue of allosteric modulators, however, limited by excessive off-target effects in lieu of excessive NMDAR inhibition. Notably, the competitive antagonists of two main substrates of NMDARs i.e. Glycine and Glutamate, targets LBD of GluN1 AND GluN2 respectively, while the Transmembrane Domain (TMD) is targeted by the channel blockers^[@CR88]^. Interestingly, Dactinomycin has been reported to rescue retinal ganglion cells from NMDA mediated excitotoxicity, suggesting potential evidence of Dactinomycin in partial inhibition of NMDA receptor^[@CR89]^. The mTOR inhibitor Everolimus has been tested in Phase 1 clinical trials for targeting glutamatergic signaling for Autism Spectrum Disorders (ASDs) and Temsirolimus have similarly been reported to be used in rodents for altering mTORpathway^[@CR90]--[@CR92]^.

Under physiological conditions, the simultaneous closure of GluN1/N2 aided by the binding energies in the advent of agonist (Glycine & Glutamate) binding puts the TMD to undergo conformational changes to open the channel^[@CR93],[@CR94]^. However, binding of NMDA-R competitive antagonist arrests the NMDA gating mechanism to an open cleft conformation of GluN1/N2 thus blocking the channel. This suggest that these drugs while interacting with residues on GluN1/N2 can interfere with NMDA gating mechanism. Specifically increased intracellular Ca^+2^ influx as a result of NMDA activation leading to increased intracellular Na^+^ by virtue of AMPA over activation may causes swelling of neuronal cell body^[@CR95]^. However, it is difficult to deduce whether interactions by compounds mimicking competitive antagonists can induce allosteric modulation on the positive or negative side. The residues Tyr 754 and Ile755 have reported to influence the binding affinities of NMDA competitive antagonist. Moreover, the NAM NVP-AAM077 and ST3 binds cavity in GluN2A harboring non conserved residues Tyr 754 and Ile755. Interestingly, these are among the same residues which have shown interaction with Dactinomycin, Temsirolimus, Everolimus, Docetaxel and Teniposide in our study. The residue Tyr754 had been proven to be of detrimental importance in site directed mutagenesis replacement with Lysine^[@CR96]^. This replacement boosted the glutamate potency thus re-sculpting the conformational states of GluN2A and altering the general behavior of glutamate binding site in GluN2A. Perplexingly, the same residue along with Lys738, also effect the Glycine binding site on GluN1. The neighboring residue Ile755 have also reported to modulate the binding cavity for negative NMDA allosteric modulators (NAMs)^[@CR96]^. The functional implication of these findings favors a potential competitive antagonistic action with possible partial NMDA inhibition. Interestingly, peripheral NMDA receptors are also drug targets to evade multidrug resistance in cancer by virtue of their ability to downregulate ABC transporters^[@CR97]^. Such is case of compound MK-801, which noncompetitively antagonizes NMDA receptor^[@CR98]^.

The AMPARs are another family members of iGluRs with structurally similar homo/hetero tetrameric organization from GluA1-A4, however differing in its preferentially Na^+^ permeability, resulting in rapid postsynaptic depolarization^[@CR99],[@CR100]^. The AMPARs have shown interactions with Dactinomycin, Temsirolimus, Paclitaxel, Vincristine, and Irinotecan with lowest binding energies among the current study's selected drug dataset (Fig. [9](#Fig9){ref-type="fig"}). Related to our findings, the role of mTORinhibitor Temsirolimus in targeting AMPAR have been reported before^[@CR90]^. To add further, Taxol has also been previously reported to selectively repress cationic influx in glutamate excitotoxicity^[@CR101]^. Paclitaxel and Vincristine have been previously documented for their involvement in mediating chemotherapy induced peripheral neuropathy (CIPN), having toxic effect on dorsal root ganglion neurons^[@CR1],[@CR102]^. However the CIPN damaging effect is also partly mediated by the induction of strong inflammatory component^[@CR103]^. Similarly, Irinotecan have been documented previously for their reduction in excitatory neurotransmission by interfering with pre and post synaptic gene expression^[@CR104],[@CR105]^. Moreover, clinical deterioration in cognitive decline in patients receiving irinotecan in combination with 5'Flourouracil has also been reported^[@CR106]^.

AMPARs have been tried with therapeutic inhibition in case of epilepsy^[@CR107]^. Past studies also suggest that triggering multiple topological conformation in the face of activity dependent interactions in AMPARs alter its mobility which may leads to its desensitization^[@CR108]^.

The current study findings showed off target interaction of Temsirolimus, Vincristine and Irinotecan with Glu 402 residue and Thr686 of GluA2 subunit of AMPA. Previous crystal structure studies of AMPAR reported interaction of Glu402 residue of subunit with Thr 686 residue which are positioned at corners of binding cleft and contributes to the stability of closed conformational state^[@CR109]^. Mutations at either of these residues result in fall of agonist binding affinities and efficacy^[@CR110]--[@CR113]^. Moreover, Hogner *et al*. reported that the inter-domain steric hindrances or remodeling of Glu402-Thr686 interaction can readjust the course of domain closure, independent of ligand affinity^[@CR109]^. Interestingly, the AMPA antagonist DNQX targets the same Glu402- Thr 686 interaction^[@CR114]^. The Gly731 residue participate in cleft closure from open to closed state^[@CR115]^. The close receptor conformational state has been associated with full agonistic behavior while a partial agonist receptor renders incomplete receptor closure. Interestingly, the L605T mutants of LBD of iGluR2 showed contrary results.

All five top docking complexes exhibit interaction with residue Tyr450. Interestingly substitution of Tyr with Ala at this position has resulted in diminution of glutamate potency^[@CR116]^. Similarly, off target interactions have also been observed at position Glu705, which had been reported to eliminate agonist binding on experimental mutation. Furthermore, experimental mutation by Armstrong *et al*., for residue Leu650 to Thr decrease the potency of AMPA receptors to Glutamate by 8.5 folds^[@CR117]^.

The GluA2 subunit of AMPA also harbors interacting residues Ser654, Thr655 and Phe658, which are flexible meta-interaction site and mutation in this region may alter binding kinetics culminating into aberrant AMPA receptor activation^[@CR118]^. Residues Tyr450, Pro478,Thr480, Ser654 AND Glu705, all directly interact with ligand to mediate strong binding^[@CR115]^. The GluA2 subunit critically regulates biophysical function by keeping in check the receptor kinetics and Ca^+2^ permeability. It is noteworthy that slowing down the AMPAR deactivation and sensitization by the use of allosteric modulators as Diazoxide^[@CR119]^ and Aniracetam^[@CR120]^ is tried in clinical studies for cognitive impairment and depression. Puzzlingly, slowing or blocking desensitization in transgenic animals led to lethal outcomes^[@CR121]^. The cumulative endpoint from past studies related with our off target interaction suggested that the deactivation kinetics of AMPARs is highly variable and any untoward off-target interaction particularly within the regions of ligand binding can potentially enhance or delay AMPA deactivation thus dysregulating excitatory postsynaptic potential (EPSP).

Evolutionarily, kinases are generally conserved and receive a high competition for substrate binding particularly from ATP in mM concentrations, thus decreasing their probability to be involved in off-target interactions^[@CR122]^, however, with the development of tyrosine kinase inhibitors and their use particularly in cancer patients, off-target interactions are not very unlikely^[@CR123]^. During LTP induction, the activity of NMDA leads to surge of intracellular Ca^+2^ triggering a biochemical cascade emanating at AMPAR mediated EPSC. This biochemical cascade is driven by CaMKII, an unusual kinase, capable of auto-phosphorylating itself (at residue T286 and T287), mediated by Ca^+2^ and Calmodulin^[@CR124]^. Moreover, it is further capable of holding its activated, the 'autonomous state', even though the initial stimulation is hold off i.e. more specifically speaking, even when the intracellular Ca^+2^ vanishes thus behaving like a 'molecular switch'^[@CR125]^. With reference to top interacting drugs with CaMKII, the list include Irinotecan, Bromocriptine, Dasatinib, Afatinib, and Imatinib (Fig. [13](#Fig13){ref-type="fig"}). Irinotecan has been previously reported to enhance neurite outgrowth by structural similarity of Polysialic Acid^[@CR126]^. Recently, the tyrosine kinase inhibitors have been shown to increase oxidative stress with resultant activation of CaMKII in cardiac fibroblasts^[@CR127]^. Interestingly, Imatinib, the first approved kinase inhibitor had been known for remarkable selectivity^[@CR128]--[@CR130]^ yet in our study it is one of the top contenders for off target interaction with CaMKII. The kinase inhibitors are however speculated to inhibit 10--100 kinases suggesting low selectivity^[@CR130],[@CR131]^.

Structurally, CaMKII have 12 subunits, each having a carboxy terminal, the Hub region, followed by a regulatory segment which harbors PTM segments for phosphorylation, NAc-Glycosylation, oxidation at position Thr287, Ser280 and Met 281 & 282 respectively^[@CR76],[@CR132],[@CR133]^. The present work analysis suggests that chemotherapeutic drugs are exhibiting off targeting interactions in the regulatory segment which spans between the residues 273--317 and the kinase domain. Residues in this region and particularly the residue Thr 286 has been proven to be essential as knocking it down will abolish LTP induction with significant memory deficits^[@CR134],[@CR135]^. The important residues participating in off target interactions include Arg 296, Arg 297, Met307 which falls in regulatory segment more specifically in the CaM recognition sequence (residues 290--314) while the residue Glu 216 comes under kinase domain. The residue Arg 297 lies at the interface of regulatory and kinase domains and is involved in hydrophobic interactions with kinase domains of other subunits. Any interference in the CaM recognition sequence may results in alteration of Ca + 2 trapping which is very crucial for the autonomous phosphorylation activity of CaMKII. Moreover, another off-target interacting residue Met 307 is in very close proximity to the Calmodulin footprint which is on residue Thr 305 and 306 and phosphorylation of these residues will abrogate CaM/Calmodulin binding^[@CR136]^ and binding with α-actinin which aids in CaMKII anchoring with NMDA^[@CR137]^.

Another cellular kinase the Protein Kinase A (PKA), contributes to LTP induction. PKA since their discovery by Kreb and coworkers, have been known to be important second messenger after cAMP^[@CR138]^. The regulatory subunit spans on multiple domains and harbors binding site for cAMP, dimerization-docking domain and a linker segment, while the catalytic subunit harbors two phosphorylation sites, one at residue Ser 338 which is near the C-terminal and the other is on residue Thr 197, coming under the activation loop/segment that serve as the docking site for protein substrate^[@CR139]^. Recent literature suggest appearance of memory deficits and long term depression (LTD) on deletion of regulatory subunits^[@CR140]^. The current investigative analysis reveals major off-target interaction from Dactinomycin, Temsirolimus, Everolimus, Docetaxel and Bromocriptine (Fig. [11](#Fig11){ref-type="fig"}). In this frame of reference, Dactinomycin has been previously reported to inhibit kinase activity by interfering at the SH2 domain which is crucial for ligand induced activation^[@CR141]^. Reduction of intracellular signal transduction by modulation of protein kinases have been reported with Bromocriptine^[@CR142]^. Contrarily, taxanes have been previously reported to pathologically enhance kinase activity promoting cell survival^[@CR143],[@CR144]^.

The off-target interactions have been shown to be involving the residues Gly 50, Thr 51, Gly 52, Ser 53, which are part of the Glycine rich loop (spanning from residue 50--55), an integral part of ATP binding site, and the residue Glu 170, part of ribose pocket, which carries the phosphate binding cassette^[@CR145]^. Interestingly, the Glycine rich loop is one of the targeted sites for the development of PKA inhibitors^[@CR77]^. Moreover, off-target interactions have also been observed in the activation loop hooking residues Phe 187, Thr 201, Pro 202 and Glu 203. Notably, the activation loop when dephosphorylated, retains in intrinsically disordered conformation^[@CR139]^. The residues from the catalytic loop have also been involved in off-target interaction.

Two decades back, English and Sweatt reported for the first time, direct involvement of extracellular signal regulated kinase (ERK) in synaptic plasticity and later it was also established that ERK activation is detrimental for L-LTP^[@CR146],[@CR147]^. This observation was further supplemented by the works of Gooney *et al*. who suggested requirement of ERK activation for BDNF induced LTP^[@CR148]^. ERK Kinase 1 and 2 which are important for LTP pathway, are related to mitogen activated protein kinase (MAPK) superfamily^[@CR149]^. Both human ERK1 and ERK2 share 84% identity and activated on parallel levels when stimulated^[@CR150],[@CR151]^.

The results suggest Dactinomycin, Bromocriptine, Temosirolimus, Everolimus and Docetaxel among top lowest scorers of mediating off target interactions with ERK2 protein (Fig. [15](#Fig15){ref-type="fig"}). All of these interactions have been appeared in protein kinase domain (23--313 residue). All these drugs exhibited interactions in the Glycine rich residues spanning between 32--37 residues. Dactinomycin is associating through hydrophobic interactions on Ala35 and Tyr36, Temisrolimus via Tyr36 hydrophobically and through Hydrogen bonding on residue Glu33. Hydrogen bonding is also on residue Glu33 and Tyr36 by Everolimus while Docetaxel is interacting on residue Ala35 both through H-bonding and hydrophobically while residue Tyr36 is receiving only hydrophobic interactions. The Lys54 residue which mediates coupling of ATP phosphates to α helix is target of off-target Hydrogen bonding by Bromocriptine, Temosirolimus, Everolimus and Docetaxel. Temsirolimus and Everolimus, both are engaged to Glu71 via Hydrogen bonding. Everolimus and Docetaxel are interfering in the corner of activation segment on the residue Asp167 by hydrogen bonding.

CBP are transcriptional coactivators known for gearing transcriptional expression of genes involved in cell survival. Moreover, CBP has also been linked to chromatin remodeling and in mediating acetyltransferase reactions^[@CR72]^. CBP mutation in Rubinstein-Taybi Syndrome has shown to be critically detrimental in LTP pathway^[@CR152]^. CREB and CBP are tools of cellular machinery imparting a central role in LTP and memory consolidation^[@CR153]^. Specifically, CREB and CBP are positioned downstream in LTP signaling cascade and phosphorylation of Serine 133 on CREB results in its activation. This triggers CREB to interact with CBP^[@CR154],[@CR155]^ via the same Ser 133 site, inducing gene expression.

The results suggest Temsirolimus, Docetaxel and Everolimus to be binding with lowest energies, in the Bromo Domain region (BRD) of CBP, however, the scores are around −8 k cal/mol. The scores are less than the top docking scores selected for studying interaction. Interestingly, the BRD has attracted particular target of interest for development of CBP BRD inhibitors^[@CR156]^. Contextually, the CBP BRD inhibition has also been linked to modulate RGS4 expression, involved in GTPase activation, by the use of Temsirolimus^[@CR157]^.

The molecular electrostatic potential analysis of the LTP pathway proteins (Fig. [17](#Fig17){ref-type="fig"}) reflected primarily electronegative charge dominance in case of NMDA and PKA while electropositivity was observed more in case of ERK and AMPA. CaMKII stands in a position where the binding interfaces is not depicting overall charge electropositivity or electronegativity which suggest its favor more towards hydrophobic interaction.

The development of kinase inhibitors have been increased tremendously during the last decade with more than 250 kinase inhibitors in the testable phase of clinical trials^[@CR158]^ However, the selectivity of kinase inhibitors have been in question by invitro studies previously^[@CR159]^. The current study findings are in alignment to the findings reported before, however, the current study identified potential offtarget interactions, suggesting new targets where the kinase inhibitors can be studied. Such is the case in mTOR signalling which has been associated with various neuropathlogies such as Autism, Epilepsy, Feeding behavior and age related synaptic alterations^[@CR160]--[@CR163]^. Moreover, mTOR pathway has been linked to LTP & Long term depression (LTD) pathways by virtue of synaptic protein translation^[@CR164],[@CR165]^. Therefore, interaction of mTOR inhibitors such as Everolimus & Temsirolimus can be detrimental. Since the chemotherapy drugs are primarily developed with the intention of targeting cancer cell proteins, the proteins with similar features are present in body elsewhere. The interaction of chemotherapeutic drugs with neuronal proteins suggest an area which is difficult to study directly on human tissues.

Moreover, some chemotherapeutic drugs, the kinase inhibitors are in clinical evaluation for treating other neurological diseases^[@CR58]^. Our study focused on some major proteins involved in LTP Pathway, however detailed elucidation of LTP dysregulation by chemotherapy requires investigation of all other proteins involved in LTP having other isoforms. Such is the case with Protein Kinase C zeta PKCζ^[@CR166]^ which is also a very important protein in LTP pathway. The absence of crystal structures of PKCζ and the intrinsically disordered nature of CREB protein^[@CR167]^ limited our interaction analysis.

The spatiotemporal kinetics of LTP proteins affected by chemotherapy can also provide useful insight. Furthermore, receptor proteins involved in LTP like NMDA and AMPA are appareled with multitude of regulatory sites imparting sensitive properties to afferent stimulus, therefore, our study's result will be case of over simplification if we generalize our findings to all NMDAR or AMPAR functionally diversified subunits. The functional implication of the off targets corresponds to the importance of LTP pathway which is crucial in neuronal learning and memory processes. On a general note, although our study identified interactions which may be linked to aberrant LTP functioning, the mechanism of chemobrain is also well reported to be linked to cytokine dysregulation and other mechanism discussed above. Therefore, chemotherapy may be on an off-targeted route, be interacting with other pathways directly linked to the proposed mechanisms of causing chemobrain, and all of these etiologies can synergistically define the resultant disease outcome of cognitive decline. Having said that, explaining the intricacies of actual proteins and pathways involved in chemobrain by off target interactions is a relatively deserted area and our study in this context may add potential links to further explore not only the chemobrain mechanisms but also to understand the LTP affected by drug target interactions.

Conclusions {#Sec20}
===========

The findings of this study suggest chemotherapy drugs to be interacting with LTP pathway proteins, which may modulate the induction and maintenance of E-LTP and L-LTP phases. As LTP is directly linked to synaptic mediation of learning acquisition and memory consolidation, the already reported aftermath of cognitive decline in chemobrain by altered LTP signaling is further objectively substantiated by this study. Moreover, regarding chemotherapy compounds in current clinical use, this study has provided novel aspects related to drug repurposing and predictive toxicology, which can help in development of more effective yet more tolerable chemotherapeutic drugs. However, further studies will be required to illustrate the agnostic and antagonistic effects of chemotherapy on LTP pathway.
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